News

April 17, 2020
Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic
April 2, 2020
Oncolytics Biotech® Announces Publication of Pelareorep’s Clinical Benefit Against KRAS Mutated Colorectal Cancer
March 24, 2020
Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
March 5, 2020
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
February 28, 2020
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
January 27, 2020
Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma
January 22, 2020
Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer
January 13, 2020
Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep’s Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
January 9, 2020
Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma
December 12, 2019
Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.com

Email Alerts Sign-Up

Secret Link